《新股消息》禮來淡馬錫參投的創勝集團傳預路演 籌2億美元
內地生物製藥公司創勝集團通過上市聆訊,聯席保薦人爲高盛及中金公司。《路透社》引述市場消息指,創勝集團正進行預路演,以評估機構投資者的需求,目標集資約2億美元。
聆訊後招股資料顯示,集團目前已自主發現及開發9種候選藥物中的8種藥物,當中包括1種核心產品及4種關鍵候選藥物,並正在開發多種前期創新生物治療候選藥物。
截至去年底止年度,創勝集團錄收入8,098萬元人民幣,按年增長83%,主要來自向合約向客戶提供合約研發生產組織(CDMO)服務;虧損則由2019年的3.95億元收窄至3.16億元。
創勝於上市前引入多名投資者,其中禮來亞洲基金(LAV)持有上市前約16.6%股權,爲主要股東。另外,淡馬錫、高瓴資本、Teng Yue Partners、私募股權基金Epiphron Capita Fund等均爲股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.